Jump Financial LLC Buys Shares of 153,231 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Jump Financial LLC bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 153,231 shares of the biotechnology company's stock, valued at approximately $1,646,000. Jump Financial LLC owned about 0.18% of Anavex Life Sciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in AVXL. Barclays PLC raised its stake in shares of Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after acquiring an additional 64,101 shares during the last quarter. Geode Capital Management LLC boosted its position in Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company's stock valued at $10,699,000 after acquiring an additional 51,946 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Anavex Life Sciences in the 3rd quarter worth approximately $74,000. Franklin Resources Inc. lifted its stake in shares of Anavex Life Sciences by 6.7% in the 3rd quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 3,674 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company's stock valued at $242,000 after purchasing an additional 1,191 shares in the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Trading Up 0.6 %

Shares of NASDAQ:AVXL traded up $0.06 during trading on Friday, reaching $9.51. The stock had a trading volume of 144,919 shares, compared to its average volume of 1,260,536. Anavex Life Sciences Corp. has a one year low of $3.37 and a one year high of $14.44. The company has a market capitalization of $808.96 million, a P/E ratio of -17.29 and a beta of 0.80. The firm's 50-day simple moving average is $8.77 and its 200 day simple moving average is $8.72.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities research analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AVXL shares. D. Boral Capital restated a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright restated a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.